Article Text

Download PDFPDF

919 Exploring new strategies for improved ADCC responses with humanized NK cells
  1. Yuan Fang,
  2. Hongyan Sun,
  3. Shiying Guo,
  4. Lingyu Song,
  5. Jun Wang,
  6. Jing Zhao and
  7. Xiang Gao
  1. GePharmatech CO. Ltd., Nanjing, Jiangsu, China
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism by which natural killer (NK) cells neutralize infected cells through antibodies. This process is mediated by CD16A, an Fc receptor (FcR) encoded by the gene FcγRIIIA which binds to IgG and activates NK cells to attack target cells. CD16A is expressed in human NK cells, but not in mouse NK cells due to the lack of the homologous gene FcγRIV. As a result, it can be challenging to accurately evaluate the effectiveness of human NK-dependent ADCC using mouse NK cells.

Methods Here we present new strategies for the reconstitution of humanized NK cells through NCG-hIL2 or NCG-hIL15 mice transplanted with CD34+ hematopoietic stem cells (HSC), greatly facilitating preclinical evaluation of the ADCC activity of antibodies.

Results Theses NK cells express NKp30, NKp46, NKG2D, CD94, and various Ig-like receptor molecules of killer cells, and produce amounts of granzyme B. There is evidence that the humanized NK cells can exhibit ADCC activity against tumor cells in vitro. Furthermore, when administered to huHSC-NCG-hIL2 mice engrafted with Trastuzumab-resistant JIMT-1 tumor cells at equivalent doses, the anti-HER2 antibody Margituximab (which has a higher affinity for CD16A) demonstrated superior anti-tumor effects than its structurally similar counterpart, Trastuzumab.

Conclusions In summary, the successful reconstruction of functional human NK cells in humanized mouse models provides a useful tool to preclinically evaluate the ADCC activity of therapeutic antibodies, potentially predicting their clinical efficacy.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.